Friday, 29 December 2017

Image Guided Surgery Devices Market will Value US$ 4,998.2 Million in 2025

According to TMR, the global image guided surgery devices market will value US$4,998.2 mn in 2025, as against its valuation of US$3,068.9 mn in 2016. Therefore, between 2017 and 2025, the global image guided surgery devices market is likely to report a CAGR of 5.7%. Regionally, the rising demand for minimally invasive surgeries and various other factors have put North America at the market’s fore in 2016. Besides this, TMR forecasts positive outlook for the market in Europe and Asia Pacific. Based on end user, the hospitals segment accounted for the highest share in the global image guided surgery devices market in 2016.


Image guided surgery devices facilitate accurate and precise diagnosis, thus bolstering the overall treatment procedure. Because of high level accuracy these devices offer, their usage has significantly increased during surgeries. Besides this, image guided devices are used as navigation systems as they guide doctors during the planning or a surgery and assist surgeons while performing one. Various factors are supporting the market’s expansion. For instance, the growing awareness regarding advanced technologies and devices has helped the market gain momentum. In addition, the market is likely to gain impetus in response to the increase willingness among patients and their families to spend on minimally invasive surgeries. Furthermore, the rising incidence of cancer, ENT problems, and osteoporosis is likely to fuel the demand for surgery devices. Also, the market will significantly benefit from technological advancements in healthcare facilities.

The escalating global population will have a positive impact on the overall market. Extensive care often become a necessity for elderly population. With age humans grow more vulnerable to illnesses. Also their low immunity level extends the recovery time in case of diseases. Considering this, in the coming years the demand for effective diagnosis and therapies is likely to get stoked in the healthcare sector. This in turn will pave way for the global image surgery devices market’s robust growth in the near future.


While developed regions will continue offering lucrative prospects, the market will gain major impetus across emerging nations. In countries such as India and China, the market witnesses major growth potential. This is due to the expansion of the healthcare industry and rising government investment toward sophisticating their healthcare infrastructure. Furthermore, medical devices can be manufactured at a reduced cost in emerging nations, without compromising on quality, which is a key factor behind the gradual shift of leading vendors towards emerging nations. However, due to lack of awareness, these companies may find it difficult to penetrate in remote areas, which could restrain the market’s growth to an extent. Nonetheless, government initiatives taken to educate and make people living in the rural areas aware about widespread diseases and their possible treatments will enable growth in the global image guided surgery devices market in the coming years.


The rising healthcare awareness, coupled with willingness to spend on advanced treatment will trigger growth in the global image guided surgery devices market. As a result of expansion reported over the years, the market is likely to witness higher competition in the near future. Besides toying with various policies to strengthen their global footprint, several market players are likely to take on strategic collaborations to attain sustainable growth in the global image guided surgery devices market. Transparency Market Research (TMR) has identified Olympus Corporation, GE Healthcare, Koninklijke Philips N.V., Siemens Healthineers, Brainlab AG, Analogic Corporation, Varian Medical Systems, Inc., KARL STORZ GmbH & Co. KG, Stryker, and Medtronic as some of the prominent companies operating in the market. Strategies aimed at business expansion adopted by these companies are likely to exert considerable influence on the market’s future trajectory.

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com

Physiotherapy Devices Market to be Worth US$ 2,838.9 Million by the End of 2025

According to Transparency Market Research, the global physiotherapy devices market was valued at US$1,686.1 mn in 2016 and is expected to reach US$2,838.9 mn by the end of 2025. During the forecast period of 2017 and 2025, the global market is expected to rise at a CAGR of 6.1%. Out of the various equipment available in the global market, the demand for electrotherapy equipment is likely to be the highest in the coming years. From a regional point of view, North America is expected to lead the global market due to growing number of physiotherapy centers and increasing awareness in the region.


Physiotherapy, is an effective healthcare treatment which helps to alleviate disability, reduce pain, restore mobility, and revive normal function. Physiotherapy often uses mechanical forces, electrotherapy, hydrotherapy, and manual forces for treating the patients. An efficient diagnosis can save the patient from a long-term ailment or a disability. Physiotherapy is predominantly used for improving the quality of life and ensuring that the patient continues to live a normal life after an injury.

Thus, physiotherapy treatment is recommended to restore the normal lifestyle for those patients who are suffering from physical immobility, and other neurological diseases. The global physiotherapy market is driven by several factors such as growing geriatric population, rising prevalence of several neurological, musculoskeletal diseases and technological advancements.

The increasing participation in sporting activities has alarmingly raised the number of injuries. To recover from sports injuries several players have to opt for physiotherapy to regain their muscle strength. Initiation of various sporting events around the world along emphasis on sports in various schools has prompted the market for physiotherapy devices. Many a time, pregnant women are also prescribed physiotherapy in order to ensure normal growth of the fetus. Thus, rise in the number of pregnancies has also spiked the demand for physiotherapy devices.


On the other hand, the global market faces some tough challenges. The lack of skilled physiotherapists is one the greatest restraint for the global market. Lack of confidence in a physiotherapist or no availability of a physiotherapist dissuades several patients from treatment. Furthermore, the high cost of equipment discourages several therapists from investing in technologically advanced devices, thereby challenging market growth. Furthermore, the poor reimbursement policies, especially in the developing parts of the world has also been identified as a restraint for the overall market in recent years.

Transparency Market Research observes that DJO Global, EMS Physio Ltd., BTL, Dynatronics Corporation, Enraf-Nonius, and Patterson Medical Ltd. are some of the leading players in the global physiotherapy devices market. As the global market faces tough competitive due to the presence of several local players, vendors are focusing on product differentiation. Offering the best possible products at affordable pricing is expected to help the companies enter untapped markets the coming years. Furthermore, international players are expected to lay emphasis on mergers and acquisitions in order to broaden their revenue-earning opportunities.


About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com

Thursday, 28 December 2017

Automated Immunoassay Analyzers Market to Reach US $3.78 Billion by the End of 2025

TMR has pegged the global automated immunoassay analyzers market at US$2.57 bn in 2016. Exhibiting a steady 4.5% CAGR between 2017 and 2025, the market is expected to reach US$3.78 bn by the end of 2025. During the course of this forecast period, Asia Pacific is likely to exhibit the highest CAGR of 4.9%. Among key end users, the market is expected to witness rising demand from diagnostic laboratories across the world.


The accelerated pace of gains witnessed in the market is aided by diverse factors. For instance, the rising incidence of chronic ailments and disease epidemics such as hepatitis infection, Zica, and HIV are among the chief factors fuelling the demand for automated immunoassay analyzers. The market is also expected to gain from the prevailing trend of preventive healthcare and laboratory consolidation. These trends have stoked the demand for laboratory automation and integration, in turn creating a landscape filled with opportunities for the global automated immunoassay analyzers market. With the demand for result comparability and international standardization scaling high, the use of automated immunoassay analyzers is likely to increase in the forthcoming years.

On the back of rising adoption of advanced technologies, the global automated immunoassay analyzers market is expected to expand considerably in the coming years. While in developed nations, the market will remaining steady, growth is likely to pace up in emerging nations. Besides rising disposable income of consumers, favorable government initiatives and investment toward betterment of the healthcare infrastructure, will help the automated immunoassay market stay strong in emerging nations.


On the downside, reeling under cost constraints, smaller diagnostic laboratories will find it particularly difficult to adopt automated immunoassay analyzers. Meanwhile in developed markets, the laboratories may face challenges on account of the declining reimbursements. Such factors are capable of restraining the market’s growth to an extent. Besides these, stringent regulations and the need for operating under escalating pricing pressures may adversely impact the market’s trajectory and also hamper the business flow of laboratories. Therefore, a majority of laboratories are focusing on high volume testing in order to boost profitability per test. In order to provide accurate diagnosis and perform specialized test, many of these laboratories have adopted automated systems. Such factors are likely to give the global automated immunoassay analyzers market significant impetus in the coming years.

Only a handful of companies such as bioMerieux, Inc., Abbott Laboratories, and Roche Diagnostics enjoy stronghold in the global automated immunoassay analyzers market. The lead of the companies is attributable to their expansive regional footprint and product portfolio, finds Transparency Market Research (TMR) in a new study. Furthermore, with a strong financial muscle, these companies are looking toward brighter prospects in the near future. As these companies gear to emerge at the fore, the global automated immunoassay analyzers market may witness roll out of novel products. Besides this, customization of existing products is on cards well. Riding on these factors the global automated immunoassay analyzers market is forecast to showcase robust expansion in the coming years.


About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com

Operating Room Management Market to Reach a Value of About US$ 3,600 Million in the Year 2022

The global operating room management market is slated to touch a value of about US$ 3,600 Mn in the year 2022 and display a robust CAGR during the assessment period.


As per the forecast of Transparency Market Research, the services segment is slated to touch a value of about US$ 2,700 Mn in the year 2022. This represents a robust CAGR during the assessment period of 2017-2022. The services segment is estimated to account for nearly three-fourths of the revenue share of the component segment by the year 2017 and is forecasted to gain market share by 2022 over 2017.

As per the forecast of Transparency Market Research, the anesthesia information management systems segment will reach a value of about US$ 550 Mn in the year 2017. This represents a robust CAGR growth during the forecast period. The anesthesia information management systems segment is forecasted to account for more than one-fourth of the total revenue share of the application segment by the end of the year 2017 and is expected to gain in market share by 2022 as compared with the year 2017.

As per the forecast of Transparency Market Research, the on-premise segment is slated to reach a value of about US$ 2,300 Mn in 2022. The on-premise segment is expected to gain market share by the end of the year 2022. The largest share is contributed by the North America region in the on-premise segment.


Transparency Market Research forecasts the United States operating room management market to exhibit a compound annual growth rate (CAGR) of nearly 13% from 2017 to 2022.

In the present times, there is an increased emphasis in the hospitals on controlling costs, to increase the overall efficiency of the operating rooms and offer world class infrastructure in the operating rooms. All these factors are boosting the adoption of operating room management and consequently the market for operating room management is growing at a steady pace. Other factors that are contributing to the growth of this market are increasing incidences of diseases and a rise in the geriatric population. With the introduction of operating room management, state of the art infrastructure facilities are provided in the operating rooms that enables the doctors and the support staff to perform maximum number of surgeries in a minimum amount of time. This enables more number of surgeries to be performed in a stipulated period of time, thereby increasing the revenues of the hospitals.

The report has also included the profiles of some of the leading companies in the operating room management market like General Electric Company, Nexus AG, Becton, Dickinson and Company, Richard Wolf GmbH, Omnicell, Inc., Steris PLC, McKesson Corp., Allscripts Healthcare Solutions, Inc., Optum Inc., Cerner Corp. and Getinge AB.


About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com

Anti-Venom Market Will Reach US$ 2,946 Million by the End of 2025

TMR forecasts the global anti-venom market to report a positive 6.8% CAGR between 2017 and 2025. At this pace the market will reach US$2,946 mn by the end of 2025. In 2016, the market was valued at US$1,653 mn. In terms of anti-venom type, the global market is bifurcated into polyvalent and monovalent anti-venom. Of these, the polyvalent anti-venom segment held the leading market share in 2016. Regionally, the Middle East and Africa held the dominant market share. However, during the course of the forecast period, the market is likely to witness highly lucrative prospects in Asia Pacific.


While the exact number of snakebites in a year is not known, the WHO estimated that nearly 5.4 million people around the world are bitten every year with 2.7 million reports of envenoming. Also there are reports of 81,000 to 138,000 deaths each year due to snake bites. These statistics clearly show a high incidence of venomous bites, which represent a serious health concern worldwide. About 3000 snake species are discovered worldwide, out of which nearly 200 species are venomous and thus hold medical importance. Also snake bites are more common in comparison to spider, scorpion or other bites. Over the years anti-venom treatment has remained the only available treatment for snakebites. This is a chief driver of the anti-venom market especially in regions such as the Middle East and Africa, Asia Pacific, and Latin America, which witness a high incidence of snakebites.

In the last couple of years, the market witnessed significant investment in research and development. Extensive studies were conducted to provide an improved understanding of immunotherapy. These studies have revealed that immunoglobulin fragments can be used to purify anti-venom thereby delivering increased efficiency and tolerance to antivenoms. On top of this modern technologies can be used for further improvement in purification and immunization procedures. While improvements in research initiatives are enabling the market gain momentum, recent advancements in diagnosis methods have paved way for its promising future. Immunologically-based techniques are used to detect the presence of specific venom antigens in the blood. Techniques such as enzyme immunoassay helps in the identification of specific species for victim’s treatment. Such developments augur well for the overall anti-venom market and is likely to support its growth through the forecast period.


On the downside, anti-venoms come at a very high cost as a result of its high cost of production and limited availability. This has emerged as a key concern for the anti-venom market, limiting its growth to an extent. Furthermore, snake bites are listed as one of the top neglected topical diseases, which is indicative of hindrances the market may have to face when penetrating in remote locations across emerging markets. Nonetheless, significant efforts are adopted at national and international levels alike to boost anti-venom production and bridge the gap between the demand and supply of the same. Such initiatives are likely to bode well for the global anti-venom market in the coming years.
Presence of several enterprises has rendered the global anti-venom market highly fragmented. In a new study, Transparency Market Research (TMR) identifies companies such as Bharat Serums and Vaccines Ltd., CSL Behring, Bio-Pharmaceutical Corporation Ltd, Vins Bioproducts Limited, Haffkine Vacsera, and Rare Therapeutics as some of the key market players. These companies adopt diverse policies and strategies to pace up with dynamic consumer preference. While a majority of the companies rely on product launches to strengthen their hold in the market, others forge partnerships and strategic collaborations to expand their regional footprint besides product portfolio.


About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com

Microbiome Sequencing Services Market to Rise to a Valuation of US$ 1,570.4 Million by 2022

According to a recent report by Transparency Market Research (TMR), the global microbiome sequencing services market is anticipated to project an impressive growth with a CAGR of 18.1% within the forecast period from 2017 to 2022. In year the global market was evaluated to be worth US$ 684.1mn. This value is likely to soar around US$ 1,570.4 mn by the end of year 2022. The sequencing by synthesis fragment ruled the worldwide microbiome sequencing services market in 2017, representing 47.8% of the worldwide market with a valuation of US$326.7 mn. The section is relied upon to display 18.6% CAGR in the 2017-2022 gauge period to ascend to a valuation of US$765.6 mn by 2022. Geographically, Europe is foreseen to remain dominant in coming years as well, with the anticipated evaluation of worth US$ 439.5 mn by the end of 2022.


The backing help to genomics research is a key driver for the worldwide microbiome sequencing services market, as it has helped players in the market accomplish better apparatuses to direct more exhaustive research. Genomics has turned into an essential instrument in the life sciences and human services segment lately because of rising mindfulness about its colossal utility in enhancing social insurance services no matter how you look at it. Therefore, private and in addition government organizations have decidedly supported the life sciences division as of late, which is probably going to remain a noteworthy driver for the worldwide microbiome sequencing services market in the coming years.

The consistent development of the biotech area in rising areas, for example, Southeast Asia and Japan is probably going to be a key driver for the worldwide microbiome sequencing services market in the coming years. The high capability of the area to enhance the indigenous social insurance division and the rising requirement for outsourcing services in the life sciences part in created nations has prompted fast request from the life sciences segment in nations, for example, India, Korea, and China. This is probably going to move the microbiome sequencing services market at a quick rate in the coming years, as a rising number of economies in this district are endeavoring to propel their indigenous medicinal services areas with a specific end goal to accommodate their growing populaces.


The global microbiome sequencing services market is prognosticated to evolve immensely in coming years. The worldwide microbiome sequencing services market is probably going to stay divided in the coming years because of the accessibility of various open doors in the market for players of all size.

Key players in the worldwide microbiome sequencing services market incorporate Microbiome Therapeutics LLC, Microbiome Insights Inc., Zymo Research Corp., Diversigen Inc., Merieux Nutrisciences Corporation, Metabiomics Corp., Rancho Biosciences, Molzym GmbH and Co. KG, Ubiome Inc., and Molecular Research LP. The significance of gut flora in people implies the improvement of the microbiome sequencing services market is personally associated with human social insurance, as concentrate the human microbiome will enable medicinal services offices to better comprehend a few conditions that are identified with the nearness of hurtful and gainful microscopic organisms. Development of the healthcare division has along these lines helped the worldwide microbiome sequencing services market extensively finished the most recent couple of years and is probably going to remain a noteworthy driver for the market soon.


About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com

Rheumatology Therapeutics Market to Become Worth US$ 52.96 Billion by 2025

A report by Transparency Market Research uncovers after in-depth study that the global rheumatology therapeutics market will rise at a lackluster CAGR of 2.7% from 2017 to 2025 to become worth US$ 52.96 bn by 2025 from US$41.88 bn in 2016.


The various drug classes in the global rheumatology therapeutics market are disease modifying anti-rheumatic drugs (DMARDs), non-steroidal anti-inflammatory drugs (NSAID’s), corticosteroids, uric acid drugs, etc. The DMARDs, which is a group of medicines or combination of medicines used to treat rheumatic diseases by blocking the inflammation, accounts for maximum share in the market at present. They are categorized into two major types - biologic DMARDs and synthetic DMARDs. By rising at a 2.6% CAGR from 2017 to 2025 the segment is expected to retain its dominant share in the upcoming years.

Geographically, the key segments of the global rheumatology therapeutics market are North America, South America, Europe, Asia Pacific, and the Middle East and Africa. Of them, North America leads the market with dominant share on account of a burgeoning geriatric population highly susceptible to various kinds of rheumatology disorders. Further, uptake of biologics and biosimilar products for treating moderate to severe rheumatoid arthritis and superior healthcare facilities has also proved beneficial to the market in the region.


Rheumatology is the multidisciplinary approach towards the diagnosis and treatment of the various rheumatic disease which includes clinical problems in joints, soft tissues, heritable connective tissue disorders, vasculitis, and autoimmune diseases. Rheumatic disease is associated with inflammation that affects the bones, tendons, ligaments, and sometimes organs.

At the forefront of driving growth in the global rheumatology therapeutics market is the ever-increasing elderly population worldwide and swift approval of new drugs for treating various rheumatic diseases. In August 2017, for example, the FDA approved DUZALLO drug by Ironwood Pharmaceuticals, Inc. and AstraZeneca. It is the first and only therapy that leverages two types of mechanisms in gout with only one pill. Again, in 2017, Kevzara (Sanofi and Regeneron Pharmaceuticals, Inc.) got the FDA approval to treat adult patients with moderately to severely active rheumatoid arthritis (RA). In 2017, AbbVie Inc., a global leader in anti-rheumatic drugs, announced its four potential candidates, which are Upadacitinib, Risankizumab, ABBV-599, and ABT-981, that are in different phases of clinical trials to treat conditions such as rheumatoid arthritis, psoriatic arthritis, and osteoarthritis (OA).

Download Report Brochure @ 

Other factors positively influencing the market are rising knowledge among people about rheumatic diseases and emergence of cost-effective rheumatology therapeutics. Further, increasing investment in research and development is likely to bolster the growth of global rheumatology therapeutics market during the forecast period.

Prominent companies operating in the global rheumatology therapeutics market are AbbVie, Inc., Pfizer, Inc., Bristol-Myers Squibb Company, Merck & Co., Inc. etc. Some other key players in the market are Amgen, Inc., Janssen Biotech, Inc., Novartis AG, Genentech, Inc., Sanofi, and Takeda Pharmaceutical.


About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com

Wednesday, 27 December 2017

Single-Use Bioreactors Market to Reach US$ 1,547.3 Million Revenue by 2026 End

Single-use bioreactors available today are robust and offers high performance which is necessary for the commercial manufacturing of biopharmaceutical products. Improvements in the bioreactor designs, film technology, sensor systems and stirring mechanisms are resulting in the increasing adoption of the single-use bioreactors. Manufacturers are also closely working with their customers to comply with the changing needs such as for next-gen gene and cell therapies, and for continuous bioprocessing. New generation single-use bioreactors are being designed while keeping in mind the processes and final drug product perspectives by the end users.


According to the latest report compiled by Transparency Market Research (TMR), the global single-use bioreactors market is expected to witness robust growth. It is also estimated to increase to 13.5% CAGR throughout the forecast period 2017-2026. The market is also projected to reach US$ 1,547.3 million revenue by 2026 end.

The global single-use bioreactors market is segmented on the basis of product type, cells type, end user and molecule type. Based on the product type, the segmentation consists of media bags, single use bioreactor systems and filtration assemblies. Among these, single use bioreactor systems are anticipated to witness significant growth throughout the forecast period. Based on the cells type, the market is categorized into bacterial cells, mammalian cells, yeast cells, and others. Between 2017 and 2026, mammalian cells are expected to witness the highest growth.

By end user, biopharmaceutical companies are anticipated to emerge as the largest users of the single-use bioreactors during 2017-2026. In the terms of molecule type, the segment includes gene-modified cells, stem cells, vaccines, monoclonal antibodies (MABS) and others. Among aforementioned molecule types, monoclonal antibodies (MABS) is likely to witness strong growth in the global single-use bioreactors market between 2017 and 2026.
Recent developments in single-use bioreactors by manufacturers are focused on improving mixing, reducing complexity, and avoid leakage and integrity issues. Improvements in the cell-culture processes are also leading to the rise in adoption of single-use bioreactors.

Europe is anticipated to be the most dominating region in the global single-use bioreactors market during 2017-2026. Owing to the presence of some of the world’s leading pharmaceutical companies in Europe, the region is likely to witness growth. The region is expected to account for the largest share, due to the patient cliff of many biologics drugs in the region and the strong support by the government to the biopharmaceutical companies in order to establish new therapies in biologics. Also, the increasing use of single-use bioreactors in cell culture-based manufacturing is driving the demand in the region. Single-use bioreactors are also becoming technologically advanced and are also being provided at competitive cost.

Meanwhile, North America and APEJ are also likely to witness growth in the single-use bioreactors market. Increasing investment by biopharmaceutical companies to establish their manufacturing facilities is driving the growth in APEJ. Increasing focus on research activities and well-established healthcare industry is resulting in the growth of the market in North America.


Some of the key market players in the report are Sartorius Merck Millipore, Stedim Biotech, GE Healthcare, Thermo Fisher Scientific, Danaher, Parker Hannifin, Eppendorf, Applikon Biotechnology, Cesco Bioengineering, Celltainer Biotech, Cellexus, PBS Biotech, Distek, Pierre Guerin, and Solida Biotech.

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com

Plasma Protease C1-inhibitor Treatment Market to be Valued at US$ 7.9 Billion by the End of 2025

According to estimations of the TMR report, the demand in the global plasma protease c1-inhibitor treatment market will expand at a strong 20.0% CAGR for the forecast period of 2017 to 2025, for the market to be evaluated at US$7.9 bn by 2025-end considerably up from its evaluated worth of US$1.5 bn in 2016. Key vendors in the plasma protease c1-inhibitor treatment market are engaged in expanding their product portfolio and expand their distribution networks in order to penetrate global markets. This has mandated vendors to meet the regulatory standards set by governing bodies at national and international level.


In terms of drug class, the global plasma protease C1-inhibitor treatment market witness maximum demand from the segment of c1-inhibitors that led amongst other segments in 2016. Geography-wise, the report assesses North America to be the most profitable market for plasma protease c1-inhibitor treatment, which accounted for a demand worth US$1,510.5 mn in 2017.

Growing investment for innovation in inhibitor drugs, promising pipeline drugs and novel therapies, and increasing awareness for hereditary angioedema (HAE) are primarily driving the plasma protease C1-inhibitor market through 2025.


One of the key drivers of the plasma protease C1-inhibitor treatment market is the increasing usage of plasma protease C1-inhibitor treatment drugs due to the increasing incidence of acute cases of hereditary angioedema (HAE) and prophylaxis. The emergence of C1-inhibitor is considered to be a major breakthrough among several drugs introduced in the plasma protease C1-inhibitor treatment market. Berinert is a C1-esterase inhibitor for acute HAE that received approval from the European Union in 2011. Haegarda, which is derived from C1-esterase inhibitor is approved in the U.S for routine prophylaxis as a preventive measure against HAE attacks in adolescents and adults.
Increasing practice of administering prophylactic treatment process for HAE patient, demand for a new route of administration of C1-inhibitor drugs, rising demand for administering drugs subcutaneously among HAE patients are some other growth drivers of the plasma protease C1-inhibitor treatment market.


Apart from this, commercialization of drugs such as Ruconest in emerging markets of Asia Pacific is likely to boost the C1-inhibitor segment in the upcoming years.

Research studies underway for the development of bradykinin B2 receptor antagonist for the treatment of HAE attacks is likely to propel the global plasma protease C1-inhibitor treatment market. At present, Firazyr is the only approved bradykinin B2 receptor for the treatment of acute HAE attack. FR 173657 is another bradykinin B2 receptor that researchers are evaluating for efficacy for acute HAE attack.

A fresh market intelligence study by Transparency Market Research (TMR) states that the business landscape of the global plasma protease c1-inhibitor treatment market is consolidated with intense competitive rivalry among leading players. TMR detects Shire plc led the global plasma protease C1-inhibitor treatment market in 2016. Key factors that account for its dominance are expanded product portfolio, acquisitions, and widespread market presence. Pharming Group N.V., CSL Limited, and Sanquin are some other key vendors that hold significant shares in the overall market for plasma protease C1-inhibitor treatment.


About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com

Membrane Separation Systems Market to Touch a Revenue Valuation of US$ 61,801.9 Million by 2025

As per estimates of a report by Transparency Market Research (TMR), the global membrane separation systems market will clock a CAGR of 9.3% for the forecast period from 2017 to 2025. Expanding at this rate, the market’s valuation of US$28,134.4 mn in 2016 will become US$61,801.9 mn by the end of 2025.


Amongst several driving factors, a significant part of the demand for membrane separation systems originates from municipal corporations. At present, measures for water reuse and wastewater treatment to save wastage of the essential commodity is the consideration of environmental agencies. This has boosted the uptake of membrane separation technologies, which in turn is stoking demand for membrane separation systems.

In particular, emerging economies that are underway rapid industrialization and facing population explosion in water-stressed areas are expected to augment the growth of this market in the upcoming years.


Membrane separation technology has emerged as the most important separation technology over the last couple of years. This is because membrane separation technology is free of chemicals, consumes less energy, and operates in an organized manner, which conventional separation techniques lack. Due to the distinct offerings of membrane separation technology, it is increasingly being used for different processes in water management, wastewater and process water treatment, food and beverage, life sciences, and pharmaceutical industries. The technology is also used for separation processes in chemical, petrochemical, and manufacturing industries.

Apart from this, several governments and metropolitan planners are awakening to the impact in the event of a shortage of water which is an everyday essentiality. This is pushing the need for innovations for water treatment, thereby paving way for the growth of the worldwide market for membrane separation systems.


The microfiltration segment, among the key technology segments, held the leading share in the global membrane separation systems market in 2016. By application, the environmental segment holds the leading share among other segments in the membrane separation systems market. Europe held the commanding share vis-à-vis revenue in the global membrane separation systems market among other key regions in 2016.

However, on the downside, high establishment and operational costs, insufficient infrastructure, and availability of other water cleaning and treatment procedures are posing a challenge to the growth of membrane separation systems market.

Amidst a fragmented vendor landscape in the global membrane separation systems market, large players that operate globally have been observed to hold supremacy in the overall market, as per one of the current reports by Transparency Market Research (TMR). In a typical scenario in this market, small scale vendors operate in regional markets serving a few end-use industries, whereas market leaders such as The Dow Chemical Company and Koch Membrane Systems Inc. not only operate globally but have serve a number of end-use industries. The topnotch companies are also upping spends on research and development to introduce innovative systems.


Pall Corporation, Sartorius AG, 3M, Amazon Filters, Advantec MFS Inc., GE Healthcare, Merck Millipore, Novasep, and TriSep Corporation (Microdyn-Nadir US, Inc.) are to name some other prominent companies in the global membrane separation systems market.

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com

Ultrasonic Electrosurgical Devices Market to Witness Widespread Expansion During 2025

Surgical energy devices are used during open as well as minimally invasive surgeries for performing procedures such as tissue cutting, dissection, and coagulation. Thermal energy generated by surgical energy devices is employed to perform these procedures. Conventional energy devices use electric energy or lasers to generate heat that performs tissue cutting, dissection, and coagulation. Developments in minimally invasive surgical procedures such as laparoscopy have led to development of ultrasonic electrosurgical devices. These devices use mechanical energy of vibrations, which generates heat. These vibrations break hydrogen bonds in a protein structure, which results in generation of extracellular and intracellular heat. This heat facilitates cutting and coagulation. Ultrasonic electrosurgical devices do not require grounding plates, which eliminates the need to pass the current through the patient’s body. This enables use of these devices in patients with metal implants such as joint implants, cardiac implants, and others.


Ultrasonic electrosurgical devices produce less heat, which avoids the charring effect. This makes them a preferred choice of surgeons in performing open and minimally invasive surgeries. These devices are being widely used in gynecology surgeries, bariatric surgeries, urology surgeries, cardiovascular surgeries, and general surgeries. Increasing prevalence of chronic diseases across the globe and rising access to health care facilities have led to surge in the number of surgeries worldwide. Rising demand for patient safety during surgeries is likely to increase the adoption for ultrasonic electrosurgical devices in the near future. Ultrasonic electrosurgical devices in the past were used for sealing of vessels measuring 3– 5 mm in diameter, while present-day devices have the ability to seal vessels measuring 7 mm in diameter. Moreover, there is no need to change the device to perform functions such as cutting, dissection, coagulation, and co-aptation. These factors are likely to drive the global ultrasonic electrosurgical devices market during the forecast period. However, ultrasonic electrosurgical consumables such as shears and blades are expensive and they have less durability compared to conventional electrosurgical devices. This factor is anticipated to restrain the market from 2017 to 2025.

The global ultrasonic electrosurgical devices market can be segmented based on product, application, end-user, and region. In terms of product, the market can be divided into generators and consumables. The consumables segment comprises handheld devices such as shears, scalpels, and blades. Most of the consumables available in the market are disposable in nature or have a limited usage cycle. This factor is likely to contribute to the leading share held by the segment. Based on application, the market can be segmented into cardiology, gynecology, general surgery, urology, bariatric surgery, and others.


The cardiology segment is likely to witness prominent growth during the forecast period. The general surgery segment is estimated to account for a leading share of the market from 2017 to 2025, owing to the large number of surgeries being performed in this segment. Based on end-user, the market can be segmented into hospitals, ambulatory surgical centers, and others. The ambulatory surgical centers segment is likely to register the maximum growth rate during the forecast period, owing to increasing number of these centers and rising number of minimally invasive surgeries.

Geographically, the global ultrasonic electrosurgical devices market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is estimated to constitute a leading share of the global market during the forecast period, owing to high adoption of technologies and high health care expenditure in the region. Europe is anticipated to account for a significant share of the global market between 2017 and 2025. Increase in the number of surgeries performed in this region is projected to fuel the market in Europe during the forecast period. The market in Asia Pacific is projected to witness high growth during the forecast period, owing to increasing health care expenditure in the region.


Major players operating in the global ultrasonic electrosurgical devices market are Ethicon Endo-Surgery (a part of Johnson & Johnson), Olympus Corporation, Medtronic, BOWA-electronic GmbH & Co. KG, Söring GmbH, Advanced Instrumentations, Reach Surgical, and ITALIA MEDICA SRL.

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com